DelveInsight’s, “Ulcerative Colitis Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ulcerative Colitis Pipeline Report
- DelveInsight’s Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
- The leading Ulcerative Colitis Companies working in the market include Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
- Promising Ulcerative Colitis Therapies in the various stages of development include ABX464, Etrasimod, adalimumab, tralokinumab, IV MK-7240, BBT-401-1S, Filgotinib, and others.
- May 2024:- AbbVie- Prospective Real World Study Of Upadacitinib in Ulcerative Colitis (PROFUNDUS). Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. This study will assess how safe and effective upadacitinib is in treating adult participants with moderate to severe ulcerative colitis (UC). Adverse events and change in disease activity will be assessed.
- May 2024:- Pfizer- An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects With Moderately to Severely Active Ulcerative Colitis. The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).
- May 2024:- Bristol-Myers Squibb- A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical Practice. The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Request a sample and discover the recent advances in Ulcerative Colitis @ Ulcerative Colitis Pipeline Outlook Report
Ulcerative Colitis Overview
Ulcerative colitis is an idiopathic inflammatory condition of the colon that results in diffuse friability and superficial erosions on the colonic wall associated with bleeding. It is the most common form of inflammatory bowel disease worldwide. It characteristically involves inflammation restricted to the mucosa and submucosa of the colon. Typically, the disease starts in the rectum and extends proximally in a continuous manner.
Ulcerative colitis can be treated with medications such as aminosalicylates, glucocorticoids, thiopurines, and biological drugs. Probiotics and fecal microbiota transplantation may also be helpful. Colectomy is curative in patients with ulcerative colitis. Colonoscopy is recommended at regular intervals due to the risk of colon cancer. There is no specific diet for patients with ulcerative colitis, but lactose intolerance is common.
Ulcerative Colitis Emerging Drugs
- Obefazimod: Abivax
Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.
- ABBV-668: AbbVie
ABBV-668 is under development for the treatment of crohn’s disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
- TEV-48574: Teva Pharmaceutical
Anti-TL1A (TEV-’574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-’574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-’574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn’s disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-’574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
- SOR102: Sorriso Pharmaceuticals
SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.
Learn more about Ulcerative Colitis in clinical trials @ Ulcerative Colitis Drugs
Ulcerative Colitis Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Ulcerative Colitis. The companies which have their Ulcerative Colitis drug candidates in the most advanced stage, i.e. Phase III include, Abivax.
DelveInsight’s Ulcerative Colitis Pipeline Report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Discover more about Ulcerative Colitis in development @ Ulcerative Colitis Clinical Trials
Ulcerative Colitis Companies
Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Ulcerative Colitis Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
To know more about Ulcerative Colitis, visit @ Ulcerative Colitis Segmentation
Scope of the Ulcerative Colitis Pipeline Report
- Coverage- Global
- Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
- Ulcerative Colitis Therapies- ABX464, Etrasimod, adalimumab, tralokinumab, IV MK-7240, BBT-401-1S, Filgotinib, and others.
For further information on the Ulcerative Colitis Pipeline Therapeutics, reach out @ Ulcerative Colitis Products Development
Table of Content
- Introduction
- Executive Summary
- Ulcerative Colitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Ulcerative Colitis– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Ulcerative Colitis Collaboration Deals
- Late Stage Products (Preregistration)
- Mirikizumab: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Late Stage Products (Phase III)
- Obefazimod: Abivax
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ABBV-668: AbbVie
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SOR102: Sorriso Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Ulcerative Colitis Key Companies
- Ulcerative Colitis Key Products
- Ulcerative Colitis- Unmet Needs
- Ulcerative Colitis- Market Drivers and Barriers
- Ulcerative Colitis- Future Perspectives and Conclusion
- Ulcerative Colitis Analyst Views
- Ulcerative Colitis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/